Riboflavin (vitamin B2), a water-soluble vitamin, is an essential nutrient in higher organisms as it is not endogenously synthesised, with requirements being met principally by dietary intake. Tissue-specific transporter proteins direct riboflavin to the intracellular machinery responsible for the biosynthesis of the flavocoenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These flavocoenzymes play a vital role in ensuring the functionality of a multitude of flavoproteins involved in bioenergetics, redox homeostasis, DNA repair, chromatin remodelling, protein folding, apoptosis, and other physiologically relevant processes. Hence, it is not surprising that the impairment of flavin homeostasis in humans may lead to multisystem dysfunction including neuromuscular disorders, anaemia, abnormal fetal development, and cardiovascular disease. In this review, we provide an overview of riboflavin absorption, transport, and metabolism. We then focus on the clinical and biochemical features associated with biallelic FLAD1
| INTRODUCTION
Riboflavin (7,8-dimethyl-10-ribityl-isoalloxazine), also known as vitamin B2, plays a role in a wide range of metabolic pathways, because it is a precursor of the essential cofactors flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) which are utilised in numerous enzymatic reactions. The human flavoproteome has a clear bias toward FAD-dependent enzymes which account for 84% of human flavoproteins, while only 16% use FMN as a cofactor. 1, 2 Flavocoenzymes are able to catalyse one-electron and two-electron transfer reactions in oxidation-reduction processes, making them key players in a number of critical metabolic processes including the mitochondrial electron transport chain, mitochondrial and peroxisomal fatty acid β-oxidation, the citric acid cycle, nitric oxide synthases, redox homeostasis, and branched-chain amino acid catabolism. These flavoproteins are also important in chromatin remodelling, DNA repair, protein folding, and apoptosis. 1 Finally, flavoenzymes also play an important role in the biosynthesis or regulation of other essential cofactors and hormones, such as coenzyme A, coenzyme Q 10 , haem, steroids, and thyroxine, as well as metabolism of other B vitamins (folate, pyridoxine/pyridoxal 5 0 -phosphate and niacin).
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| DIETARY SOURCES OF RIBOFLAVIN
Riboflavin, as with other water-soluble B vitamins, must be obtained through the diet, since higher organisms have lost the ability to synthesise this molecule as opposed to various plants, fungi and bacteria. Endogenous synthesis of riboflavin (from ribulose-5-phosphate and GTP) by bacteria in the large intestine may contribute to some extent. 4 The recommended daily allowance of riboflavin on average is 1.3 mg/d for adult men and 1.1 mg/d for women, with variations depending on age and reproductive status including pregnancy and lactation. 4 Milk and dairy products are the largest sources of riboflavin in the Western diet, making up 51% of intake in preschool children, 35% in school children, 27% in adults, and 36% in the elderly. 5 Due to the adequate availability of riboflavin in a wide variety of food sources, isolated deficiency is not prevalent in the general population, apart from rare genetic defects and malabsorptive conditions. 6 
| RIBOFLAVIN TRANSPORT AND METABOLISM
Riboflavin ingested in the diet exists either as free riboflavin or its protein bound form as flavoproteins containing FAD and FMN. Milk and eggs contain free riboflavin, but most other foods tend to predominantly contain FAD and FMN, which must be released from the carrier proteins to which they are bound. This is achieved by protein denaturation in the stomach, and subsequent hydrolysis to free riboflavin by alkaline phosphatases and FMN/FAD pyrophosphatases in the brush border of the ileal enterocyte, allowing absorption in the small intestine. 7 Three human plasma membrane riboflavin transporters have been characterised ( Figure 1A ): RFVT1 (previously hRFT1), RFVT2 (hRFT3), and RFVT3 (hRFT2), encoded by SLC52A1, SLC52A2, and SLC52A3, respectively. 8 These three transporters have different subcellular locations and tissue specificities. 4, 8 Free riboflavin is transported into enterocytes via carrier-mediated uptake by RFVT3, 8 a saturable transport process at the apical membrane which is reported to be linear up to approximately 30 mg riboflavin per meal, 5,9,10 and beyond which little additional absorption of riboflavin occurs.
5,11
After cellular uptake, riboflavin is quickly transformed into its catalytically active cofactors by the action of two enzymes: riboflavin kinase (RFK) (EC 2.7.1.26) and FAD synthase (FADS) (EC 2.7.7.2) which catalyse FMN and FAD production, respectively ( Figure 1B ). Riboflavin may be released into the portal blood and to the liver in its free form or as FMN after being transported by RFVT1 and RFVT2 which are embedded within the basolateral membrane of enterocytes. 4 Circulating plasma riboflavin is bound to either albumin or immunoglobulins or is converted into its coenzyme forms in erythrocytes or leukocytes. Median plasma concentrations for riboflavin, FMN, and FAD have been reported to be 10.5, 6.6, and 74 nmol/L.
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Key Messages
• Riboflavin is an essential nutrient in higher organisms since it is not endogenously synthesised and must be supplied through dietary intake.
• Primary defects of flavocoenzyme metabolism include genetically inherited disorders:
involving enzymes in the synthetic pathway of essential cofactors FMN and FAD (ie, FAD synthase deficiency; to date, no cases of human riboflavin kinase deficiency have been reported).
disorders of riboflavin or flavocoenzyme transport.
• Secondary flavocoenzyme defects refer to the functional disruption of the cellular flavoproteome, that is, cofactor dependent reactions which do not arise as a direct result of defects in the synthesis or transport of cofactors. Examples include multiple acyl-CoA dehydrogenase deficiency (MADD), glutaric aciduria type 1, and dihydrolipoamide dehydrogenase deficiency.
• Both primary and secondary flavocoenzyme deficiencies may present with abnormal biochemical features including characteristic elevations of plasma acylcarnitines and urinary organic acids.
• Riboflavin therapy may be beneficial in both primary and secondary flavocoenzyme deficiencies, hence early recognition of these disorders is imperative.
RFK is a ubiquitous rate-limiting flavokinase that catalyses the first step in FAD biosynthesis by phosphorylating riboflavin to form FMN, 13 which is subsequently adenylated by FADS to generate FAD. 14 The crystal structure of human RFK revealed a six-stranded antiparallel beta-barrel core that complexes with both riboflavin and ADP. 13 RFK has also been shown to be a tumor necrosis factor (TNF) receptor-1 (TNFR1)-binding protein that physically and functionally couples TNFR1 to NADPH oxidase. TNF, through the activation of RFK, enhances the incorporation of FAD into NADPH oxidase, which is critical for the assembly and activation of NADPH oxidase. 15 FADS catalyses the adenylation of FMN to FAD. 14 In humans, distinct isoforms of this enzyme are distributed in different subcellular compartments and generated by alternative splicing of the FLAD1 gene. 4, [16] [17] [18] The most abundant of these isoforms, that is, the cytosolic enzyme or isoform 2, has been shown to be a bifunctional enzyme with both FADS and hydrolase activity. 19 The enzyme contains an Nterminal molybdopterin binding (MPTb) domain which has FAD hydrolase activity, and a C-terminal 3 0 -phosphoadeno- SLC25A32 is an inner mitochondrial membrane carrier that imports FAD from the cytosol into mitochondria (mitochondrial FAD-transporter; Figure 1B ), where it is needed for the many FAD-dependent mitochondrial enzymes, including components of the respiratory chain and the fatty acid beta oxidation spiral. SLC25A32 was initially identified as a mitochondrial folate transporter, 22 before it was demonstrated to be the human orthologue of the yeast mitochondrial FAD transporter FLX1. 23 The mitochondrial translocator FLX1
catalyses the bidirectional movement of the redox cofactor FAD across the mitochondrial membrane. 24 The possibility that SLC25A32 regulates FAD efflux from the mitochondrial matrix to the cytosol has been neither confirmed nor excluded in human cells. Unbound flavins are rapidly hydrolysed to free riboflavin and excreted in urine. Riboflavin is not stored in the body, hence any intake in excess of tissue requirements or which surpasses renal reabsorption, is eliminated in the urine as F I G U R E 1 (A) Dietary flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) are converted to riboflavin by hydrolases at the brush border of ileal enterocytes. Riboflavin is then absorbed into the intestine via apically expressed RFVT3 (also known as hRFT2) and released into portal blood by basolaterally expressed RFVT1 (also known as hRFT1) and RFVT2 (also known as hRFT3). Circulating plasma riboflavin is transported in blood bound to either albumin or immunoglobulins. RFVT2-mediated transport allows riboflavin uptake into the brain. The precise mechanism of import of riboflavin into the mitochondrial matrix has not been established to date. We have depicted RFVT? as a putative riboflavin transporter responsible for this step. Subsequent conversion into flavocoenzymes occurs in tissue cells, as shown in (B). The mitochondrial FADtransporter (FADT) is an inner mitochondrial membrane carrier that imports FAD from the cytosol into the mitochondria. The question mark indicates that FADT-mediated efflux of FAD from the mitochondrial matrix to the cytosol remains to be established. See also Barile et al. 4 (B) After cellular uptake of riboflavin, flavocoenzymes are formed by a sequential pathway involving riboflavin kinase and FAD synthase. Both steps require ATP. Zn 2+ is the preferred metal ion which facilitates the γ-phosphate exchange catalysed by riboflavin kinase, whilst Mg 2+ is used in the adenylation catalysed by FAD synthase riboflavin or its catabolites 7-alpha-hydroxy riboflavin, 10-hydroxyethylflavin and lumiflavin. 4, 25 This means that riboflavin has a relatively low toxicity even at suprapharmacological doses. 4 
| RIBOFLAVIN DISORDERS IN HUMANS
| Nutritional riboflavin deficiency
Since riboflavin is not endogenously synthesised or stored in human tissues, adequate dietary intake is imperative. Clinical problems associated with dietary deficiency of riboflavin, also known as ariboflavinosis, include night blindness, cataracts, fatigue, anaemia, growth retardation, migraines, peripheral neuropathy, and dermatological symptoms (cheilosis, glossitis, scaly skin rashes confined to the scrotum and vulva, and chapped lips). 26 Low riboflavin intake during pregnancy may be associated with an increased risk of congenital heart disease. 27 Symptomatic riboflavin deficiency often occurs in association with deficiencies of other vitamins and has usually been attributed to dietary restriction; however, it is potentially more widespread than currently recognised with an estimated 10% to 15% of the global population having an inherited restriction in their ability to absorb or utilise riboflavin. 3, 28 Supplementation for prevention of ariboflavinosis is generally not necessary as adequate amounts of riboflavin are available in a healthy diet, except when the diet is very limited or other health issues are present. Riboflavin deficiency can, however, occur during lactation, phototherapy in infants, or as a consequence of coeliac disease, alcoholism, malignancies, or use of prescription drugs including phenothiazine-derived antipsychotic medications, the antimalarial drug quinacrine, phenobarbital and the cancer chemotherapy agent adriamycin. Two patients with biallelic mutations in SLC25A32 encoding the mitochondrial FAD transporter have been reported. 35, 36 The first was a 14-year-old girl with riboflavin-responsive recurrent exercise intolerance and biochemical features of MADD. 36 The second patient, 51 years old at the time of reporting, presented at 3 years with muscle weakness following an episode of influenza, and subsequently had progressive exercise intolerance in childhood, together with neurological symptoms including early-onset ataxia, myoclonus, dysarthria, and dysphagia. 35 Muscle biopsy revealed ragged-red fibres, lipid storage and fibres with decreased staining for succinate dehydrogenase (SDH, FAD-dependent mitochondrial respiratory chain complex II), and cytochrome c oxidase (COX, mitochondrial respiratory chain complex IV) in both patients. Deficiency of complex II was demonstrated in muscle from the second patient and cultured skin fibroblasts from the first patient. 35, 36 Both patients had dramatic improvements in the clinical and biochemical abnormalities following oral riboflavin supplementation, including improved exercise tolerance and endurance. 35, 36 It is interesting that these patients have a MADD-like predominantly myopathic presentation, quite distinct from the neuropathic presentation of patients with mutations in the plasma membrane riboflavin transporters RFVT2 and RFVT3.
| Primary defect of riboflavin coenzyme metabolism 4.3.1 | FAD synthase deficiency (OMIM # 255100)
In the last few years, biallelic variants in FLAD1 encoding FADS have been identified as causing a potentially treatable neuromuscular disease manifesting with lipid storage myopathy and metabolic abnormalities suggestive of MADD, in association with multiple respiratory chain enzyme deficiencies. 17, 37 Thirteen patients have been reported in the literature to date, all but one patient 38 were identified by whole-exome sequencing or through candidate gene panels, and their clinical features are summarised in Table 1 all of these infants included hypotonia and severe muscle weakness leading to feeding difficulties (poor suck and swallow, frequently necessitating tube feeding) and respiratory insufficiency. One patient presented with cardiorespiratory collapse at 32 hours of age and died at 3 days. 17 Another had cardiomyopathy in the first year of life and recurrent supraventricular tachycardias necessitating implantable cardioverter defibrillator placement. This infant had a dramatic response to riboflavin supplementation and was still alive at 22 years. 17 Another infant who needed a pacemaker because of recurrent episodes of sudden cardiac arrest died of multiorgan failure at 7 months. 17 Eight of the 11 cases with an infantile onset died, 7 within the first 9 months of life and the eighth at 16 years. 17, 37, 40 Three children who presented in infancy were alive, two at 8 years and the third at 22 years, all treated with riboflavin. Two individuals presented in adult life, at 20 and 44 years, and were alive at 44 and 56 years, respectively. 17, 39 The adultonset cases presented with exercise intolerance and progressive muscle weakness, with gait difficulties, bilateral foot drop and arm weakness in the older patient. 17, 39 Blood and urine biochemistry in FADS deficiency are typical of riboflavin deficiency or MADD, with increased acylcarnitines and urinary organic acids in all cases tested ( Table 2 ). Elevations of C4-C14 even chain acylcarnitines, C5 and C5-DC and C10:1, C14:1, C16:1, C18:1, and C18:2 have all been reported. 17, 40 In one infant only C4 was elevated, and in another the acylcarnitine profile was normal on some occasions and abnormal on others. 17 Increased urinary excretion of ethylmalonic, adipic, suberic, glutaric and methylsuccinic acids, hexanoylglycine, and tiglylglycine has been observed. 17, 38, 40 There appears to be a characteristic muscle pathology in FADS deficiency, with pronounced lipid storage and a global decrease of COX and/or SDH histochemical staining. 37 Ragged-red fibres have not been reported so far. Multiple respiratory chain enzyme deficiencies were observed in skeletal muscle biopsies in seven of eight cases tested, variably affecting complexes I, II, III, and/or IV. 17, 37, 40 One case was said to have normal muscle respiratory chain enzyme activities. 17 Decreased FADS activity was demonstrated in cultured skin fibroblasts from all four patients tested. 17, 38 Nine of the 13 patients reported with FADS deficiency were Turkish, and three different homozygous FLAD1 mutations were observed in this population (Table 1) . One mutation appears to be particularly prevalent, suggesting a possible founder effect. This is a 4 bp deletion (c.401_404delTTCT, initially reported as c.397_400delTTCT) in the MPTb domain resulting in a frameshift and premature termination (p. (Phe134CysfsTer8)), and was observed in five infants from four families. 17, 37, 40 All five died between 4 and 8 months of age. A possible genotype-phenotype correlation has been suggested. 17 Three of four individuals with at least one FADS domain mutation affecting a single amino acid had prolonged survival (alive at 22-56 years), although the fourth died at only 3 days of life. Conversely, all eight patients with biallelic frameshift mutations in the MPTb domain died, almost all in infancy (Table 1) . One individual diagnosed with MADD on newborn screening was treated with riboflavin for the first 29 months of life, but developed a progressive myopathy from 3 years of age and was found to have a homozygous nonsense mutation in the MPTb domain of FLAD1 at 8 years. 38 The nonsense mutation led to a truncated protein with some residual FADS activity. 38 Clearly only a small number of patients with FLAD1 mutations have been identified so far, and so it is difficult to make firm genotypephenotype predictions at present. Riboflavin supplementation resulted in clinical improvements in seven of eight patients treated, 17, 38, 40 including dramatic amelioration of muscle symptoms and an increase in muscle strength, and improvements of the biochemical abnormalities in one adult patient who was further described in a subsequent report. This individual also received dietary therapy with high carbohydrate, moderate protein, and low fat (max. 20 g fat/day), which was reported to ameliorate her symptoms. 39 Treatment with riboflavin at age 3 months in two patients homozygous for the c.401_404delTTCT mutation in FLAD1 seemed to result in mild improvements in spontaneous activity, muscle tone, vomiting, and alertness, but failed to prevent disease progression; both infants died before the age of 6 months. 40 It has been proposed that biallelic frameshift mutations in exon 2 of FLAD1 may be partially responsive to riboflavin supplementation, 17 but the doses used so far have not led to long-term survival. 40 Studies of the overexpressed mutant proteins in Escherichia coli demonstrated that FAD supplementation significantly improved protein stability and/or folding of the mutated proteins, supporting a chaperone-like action of FAD.
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Of note, riboflavin treatment initiated in the newborn period may have attenuated an otherwise severe phenotype in an 8-year-old boy with a homozygous nonsense mutation in FLAD1 who initially presented with MADD biochemical abnormalities in the newborn screening test. 38 In summary, all patients with FADS deficiency should receive high-dose riboflavin therapy, and if the diagnosis is suspected riboflavin supplementation should be implemented while awaiting mutational analysis, with subsequent withdrawal if the diagnosis is not confirmed. The benefits of early diagnosis and treatment are exemplified by discordant outcome between treated and untreated siblings. 17 The potential avenue of prenatal or presymptomatic postnatal treatment with high dose riboflavin that may prevent or ameliorate the disease symptoms has been raised but requires further exploration. Other future therapeutic strategies include enhancing the activity of the truncated FADS isoform 6 20 or the mitochondrial FAD transporter in those patients who do not benefit from riboflavin. 40 
| Riboflavin kinase deficiency
RFK deficiency has never been reported in humans. It is possible that this might be incompatible with life since, as discussed above, RFK is the rate-limiting step in the synthesis of FAD, an essential cofactor for many cellular reactions.
In support of this hypothesis, RFK deficiency was embryonic lethal before day 7.5 of gestation in a knockout mouse model. 15 However, it is possible that hypomorphic RFK mutations may result in a clinical presentation similar to that seen in patients with FLAD1 mutations. Whole-exome and whole-genome sequencing of undiagnosed patients with lipid storage myopathies and MADD-like clinical presentations may identify affected cases in the fullness of time.
T A B L E 2 Biochemical abnormalities reported in FADS deficiency
Abnormality Number % Of those tested Reference(s) 
| Disorders of the human flavoproteome
The human flavoproteome has been reported to comprise at least 90 distinct proteins, with diverse roles as indicated above (also see Table 3 ). 2 Human diseases have been associated with approximately half of these proteins and are clinically extremely heterogeneous, including Leigh syndrome and other mitochondrial respiratory chain disorders, mitochondrial and peroxisomal fatty acid oxidation (FAO) disorders, pyridoxal phosphate responsive epilepsy, trimethylaminuria, rhizomelic chondrodysplasia punctata, porphyria variegata, chronic granulomatous disease, and defects of steroidogenesis and bile acid synthesis (Table 3) . Riboflavin responsiveness has not been reported for many of these disorders, and for several conditions it is not clear whether therapeutic trials of pharmacological doses of riboflavin have been explored as potential treatments. A full description of all disorders of the human flavoproteome is beyond the scope of this review, but some of the mitochondrial disorders associated with riboflavin responsiveness are discussed briefly below. MADD (OMIM #231680) is caused by deficiency of electron-transfer flavoprotein dehydrogenase (encoded by ETFDH) or of one of the two electron-transfer flavoproteins (encoded by ETFA and ETFB) which transfer electrons from acyl-CoA dehydrogenases to coenzyme Q 10 in the mitochondrial respiratory chain. 41 Clinical phenotypes associated with MADD are heterogeneous and have been classified into a severe neonatal onset multsystemic form and a milder later onset myopathic form. The latter is the most frequent clinical presentation, manifesting as exercise intolerance, occasionally respiratory insufficiency or rhabdomyolysis and is typically riboflavin responsive. 42, 43 Other cases may have a secondary coenzyme Q 10 deficiency. 44 Riboflavin supplementation has successfully ameliorated clinical symptoms and metabolic abnormalities in over 95% of patients with late-onset MADD patients, the majority of whom (93%) have ETFDH mutations.
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ACAD9 is a bifunctional enzyme primarily involved in complex I biogenesis, with an additional moonlighting function in FAO. 45 The major clinical presentations of ACAD9 deficiency are early-onset cardiac involvement ranging from isolated electrical hypertrophy to severe hypertrophic, dilated or combined cardiomyopathy, exercise intolerance and myopathy, lactic acidosis and neurological abnormalities including stroke-like episodes, ataxic gait, bradykinesia, and bradylalia. 46 ACAD9
mutations are the most frequent cause of hypertrophic cardiomyopathy with isolated complex I deficiency. 47 Riboflavin has been shown to directly increase ACAD9 protein levels and rescue complex I assembly and may also function as a chemical chaperone by improving the folding of specific ACAD9 mutant proteins. 45 Therapeutic response to riboflavin supplementation was reported in 65% of treated patients in one large multinational cohort of ACAD9 deficiency. 48 Riboflavin responsiveness has also been reported in other forms of complex I deficiency. 49 It is possible that FMN may stabilize the complex I holoenzyme. Dihydrolipoamide dehydrogenase (also known as E3, encoded by DLD) is a flavoprotein shared by three mitochondrial α-ketoacid dehydrogenase multienzyme complexes: pyruvate dehydrogenase complex (PDHc), α-ketoglutarate dehydrogenase complex (KGDC), and branched-chain α-keto acid dehydrogenase complex (BCKDC). The metabolic derangements reflect PDHC and TCA cycle defects, and include increased blood lactate and pyruvate, elevated plasma alanine, branched-chain amino acids and increased urinary lactic, pyruvic, 2-ketoglutaric, and branched-chain 2-hydroxyand 2-ketoacid. 50 The phenotypic spectrum of DLD deficiency is variable, and encompasses early onset encephalopathy with progressive hypotonia, failure to thrive, hypoglycemia, ketoacidosis and encephalopathy, Leigh syndrome, and a recurrent Reye-like presentation with normal intellect and no residual neurologic deficits between acute metabolic episodes. 51 A riboflavin-responsive myopathic phenotype with exertional fatigue, intermittent elevation of blood lactate, ketoacidosis, elevation of creatine kinase, and mitochondrial proliferation has also been described. 52 Riboflavin supplementation led to complete resolution of muscle weakness, improvement of metabolic abnormalities, partial restoration of the DLD protein, and reduced ROS production in fibroblasts, supporting a chaperone-like effect of riboflavin promoting DLD protein stability and folding.
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The X-linked AIFM1 gene encodes apoptosis-inducing factor (AIF), a mitochondrial flavoprotein with a dual role as an FAD-dependent NADH oxidoreductase involved in oxidative phosphorylation and redox control and also as a caspase-independent death effector mediating programmed cell death when translocating from mitochondria to the nucleus on exposure to apoptotic stimuli.
53 AIFM1 mutations have been associated with a wide spectrum of clinical phenotypes ranging from a severe, early-onset mitochondrial encephalomyopathy with combined oxidative phosphorylation deficiency (OMIM #300816), 54 to Cowchock syndrome, an X-linked Charcot-Marie-Tooth disease with axonal sensorimotor neuropathy, sensorineural deafness, and cognitive impairment (CMTX4, OMIM #310490).
55
Recently, AIFM1 mutations have been reported to cause cerebellar ataxia partially responsive to riboflavin. 56 
| CONCLUSIONS
There is increasing evidence for a potential role of riboflavin in the prevention and treatment of various primary or secondary defects of maintenance of the cellular flavoproteome. In recent years, defects of FADS in the flavocoenzyme biosynthetic pathway, the plasma membrane riboflavin transporters and the mitochondrial FAD transporter have all been linked to human disease. Human RFK deficiency remains to be described. It is not known why the plasma membrane riboflavin transporter disorders manifest predominantly as a neuronopathy (BVVL) whereas defects of mitochondrial FAD transport and FAD synthesis are associated with myopathic phenotypes. Further research will be needed to unravel this enigma. Because of the potential beneficial effect of riboflavin in both primary and secondary flavocoenzyme deficiencies, early recognition of these disorders is imperative. Supra-pharmacological doses of riboflavin are required for inborn errors associated with primary flavocoenzyme deficiency, and response to treatment may be more variable in patients with secondary deficiency. 
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